- Home
- LOT vs JANX Comparison
LOT vs JANX Comparison
Compare LOT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- JANX
- Stock Information
- Founded
- LOT 1948
- JANX 2017
- Country
- LOT China
- JANX United States
- Employees
- LOT N/A
- JANX N/A
- Industry
- LOT
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- LOT
- JANX Health Care
- Exchange
- LOT NYSE
- JANX Nasdaq
- Market Cap
- LOT 3.4B
- JANX 2.9B
- IPO Year
- LOT N/A
- JANX 2021
- Fundamental
- Price
- LOT $4.51
- JANX $48.52
- Analyst Decision
- LOT
- JANX Strong Buy
- Analyst Count
- LOT 0
- JANX 10
- Target Price
- LOT N/A
- JANX $65.10
- AVG Volume (30 Days)
- LOT 136.1K
- JANX 675.5K
- Earning Date
- LOT 11-21-2024
- JANX 11-06-2024
- Dividend Yield
- LOT N/A
- JANX N/A
- EPS Growth
- LOT N/A
- JANX N/A
- EPS
- LOT N/A
- JANX N/A
- Revenue
- LOT $947,088,000.00
- JANX $13,049,000.00
- Revenue This Year
- LOT $61.26
- JANX $66.30
- Revenue Next Year
- LOT $62.92
- JANX N/A
- P/E Ratio
- LOT N/A
- JANX N/A
- Revenue Growth
- LOT 590.43
- JANX 54.12
- 52 Week Low
- LOT $4.15
- JANX $7.79
- 52 Week High
- LOT $17.99
- JANX $65.60
- Technical
- Relative Strength Index (RSI)
- LOT 49.81
- JANX 39.32
- Support Level
- LOT $4.27
- JANX $50.51
- Resistance Level
- LOT $4.59
- JANX $57.48
- Average True Range (ATR)
- LOT 0.25
- JANX 2.86
- MACD
- LOT 0.04
- JANX -0.81
- Stochastic Oscillator
- LOT 60.27
- JANX 0.66
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.